Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term lucerastat in Japanese Fabry disease patients
jRCT2080224890Phase 3Completed
- Sponsor
- Nxera Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Nxera Pharma. Primary endpoint: Long-term safety and tolerability of lucerastat. Started Sep 2019; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT2080224890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224890.